DNA blood test may spot nasopharyngeal cancer earlier than current methods
NCT ID NCT06763289
First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time
Summary
Researchers are testing whether a blood test that looks at DNA methylation patterns can find nasopharyngeal carcinoma earlier and more accurately than the standard Epstein-Barr virus (EBV) tests. The study will compare the new multi-omics model with EBV DNA quantification and two antibody tests in 700 adults aged 40 to 74, some with cancer and some without. The goal is to see if the DNA-based approach reduces false negatives and false positives, improving early detection and avoiding unnecessary procedures.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Blood-based multi-omics screening model using DNA methylation and fragmentome analysis, compared with standard EBV DNA quantification and EBNA1-IgA/VCA-IgA antibody tests
- What this could lead to
- If successful, this could lead to a more accurate blood test for early nasopharyngeal carcinoma, reducing false negatives and false positives compared to current EBV-based methods.
- What could go wrong
- This is a comparison study, not a treatment trial, so it won't directly improve outcomes. The new model may not outperform existing tests in real-world settings, and results depend on the specific population studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 700 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Confirmed cancers or individuals without confirmed cancer will be invited to participate in this case-control study by a designated consenting professional.
- Ages
-
40 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for Case Arm Participants: 1. 40-74 years old 2. Clinically and/or pathologically diagnosed cancer 3. No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc. 4. Able to provide a written informed consent and willing to comply with all part of the protocol procedures Exclusion Criteria for Case Arm Participants: 1. Pregnancy or lactating women 2. Known prior or current diagnosis of other types of malignancies comorbidities 3. Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen 4. Recipients of organ transplant or prior bone marrow transplant or stem cell transplant 5. Recipients of blood transfusion within 30 days prior to screen 6. Recipients of therapy in past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide 7. Unsuitable for this trial determined by the researchers Inclusion Criteria for Control Arm Participants: 1. 40-74 years old 2. Without confirmed cancer diagnosis 3. Able to provide a written informed consent and willing to comply with all part of the protocol procedures Exclusion Criteria for Control Arm Participants: 1. Pregnancy or lactating women 2. Known prior or current diagnosis of other types of malignancies comorbidities 3. Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen 4. Recipients of organ transplant or prior bone marrow transplant or stem cell transplant 5. Recipients of blood transfusion within 30 days prior to screen 6. Recipients of therapy in the past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide 7. Unsuitable for this trial determined by the researchers
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nasopharyngeal carcinoma (NPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Million-Person quest to catch a silent cancer early
- Can a new drug combo shrink High-Risk throat tumors?
- Can a lower radiation dose still beat nasopharyngeal cancer?
- Can a new drug combo keep advanced nasopharyngeal cancer at bay?
- Can a Two-Drug attack shrink recurrent throat cancer?
- Could avoiding Pre-Radiation tooth removal protect jaw health?